Evolent Health Announces Third Quarter 2018 Results

WASHINGTON, Nov. 6, 2018 /PRNewswire/ -- Evolent Health, Inc. EVH, a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial results for the quarter ended September 30, 2018.

Highlights from the third quarter of 2018 announcement include (all comparisons are to the quarter ended September 30, 2017):

• GAAP revenue of $149.9 million, an increase of 39.0%; Adjusted Revenue of $150.2 million, an increase of 38.6%
• Net income (loss) attributable to Evolent Health, Inc. of $(12.4) million, Adjusted EBITDA of $4.8 million
• Lives on platform of approximately 3.1 million, an increase of 16.4%
• Expanded opportunity with SOMOS IPA ("SOMOS"). The New York State Department of Health recently announced that SOMOS has been approved to participate in the Innovator program. Working closely with Evolent, SOMOS intends to contract with Managed Care Organizations (MCOs) to take on delegated risk and coordinate care for Medicaid enrollees in the greater New York metropolitan region.
• Entered into a definitive agreement to acquire New Century Health ("NCH"), a technology-enabled, specialty care management company focused primarily on cancer and cardiac care supporting approximately 462,000 Medicare Advantage lives. As of the October 1, 2018 transaction close date, NCH is a full subsidiary of Evolent Health.

Frank Williams, Chief Executive Officer of Evolent Health, Inc., commented, "We are quite pleased with our third quarter results and our continued strong performance in 2018. Coupled with the recent positive movement in the health care policy environment, our success in driving clinical and financial improvement for our partners has served as a catalyst in growing our pipeline and adding nine new partners to the Evolent network this year."

Mr. Williams commented, "We are delighted to announce that one of our new partners, SOMOS, has received a new contracting designation as a Value-Based Payment Innovator in New York. As a participant in the Innovator program, SOMOS is now able to pursue delegated risk arrangements with MCOs responsible for more than one million Medicaid managed care lives in the greater New York metropolitan region. We look forward to supporting SOMOS in its clinical operations as a Value-Based Payment Innovator and continuing to support its efforts in New York State's Delivery System Reform Incentive Payment program. As an organization with such deep ties to the communities it serves, SOMOS is well-positioned to make a significant impact on the health of New York's Medicaid population."

Mr. Williams added, "We are also pleased to report that, together, our Evolent teams and Medicaid partners in Florida—Lee Health, Baptist Health Care and Nicklaus Children's Health System—are making great strides to meet the state regulator's readiness requirements for the launch of three new Medicaid health plans. The plans are slated to begin operations at staggered start dates across late 2018 and early 2019, and we're excited to see the value these provider-led plans can bring to thousands of beneficiaries in one of the largest Medicaid populations in the U.S."

Mr. Williams concluded, "As we approach the end of 2018, the Evolent team is highly focused on driving strong results for our network, which has surpassed 35 partners. The team is also focused on onboarding several new partners at the beginning of 2019. We are excited about the addition of NCH to our portfolio of solutions focused on managing total cost of care. NCH has a proven track record of delivering impressive results for its partners, both from a clinical quality and financial standpoint in the specialty care management areas of oncology and cardiology. We look forward to collaborating with the talented NCH team and exploring a number of market opportunities going forward."

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss non-GAAP financial measures. Definitions of the non-GAAP financial measures, as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings release. See "Financial Statement Presentation" and "Non-GAAP Financial Measures" for more information.

Reported Results

Evolent Health, Inc. reported the following United States of America generally accepted accounting principles ("GAAP") results:

• Total revenue of $149.9 million and $107.9 million for the three months ended September 30, 2018 and 2017, respectively, an increase of 39.0%;
• Services revenue of $130.9 million for the three months ended September 30, 2018, before intersegment eliminations of $(3.5) million; and
• True Health premiums revenue of $22.8 million before intersegment eliminations of $0.2 million.
• Cost of revenue of $74.0 million and $68.3 million for the three months ended September 30, 2018 and 2017, respectively, an increase of 8.3%;
• Claims expenses of $17.0 million for the three months ended September 30, 2018;
• Selling, general and administrative expenses of $59.6 million and $45.8 million for the three months ended September 30, 2018 and 2017, respectively, an increase of 30.0%;
• Net income (loss) attributable to Evolent Health, Inc. of $(12.4) million and $(12.6) million for the three months ended September 30, 2018 and 2017, respectively;
• Earnings (loss) available to common shareholders, basic and diluted, of $(12.4) million and $(12.6) million for the three months ended September 30, 2018 and 2017, respectively; and
• Earnings (loss) available to common shareholders, per basic and diluted share, of $(0.16) and $(0.18) for the three months ended September 30, 2018 and 2017, respectively.

Total cash and cash equivalents as of September 30, 2018, were $221.8 million.

Adjusted Results

• Adjusted Revenue of $150.2 million and $108.4 million for the three months ended September 30, 2018 and 2017, respectively, an increase of 38.6%;
• Adjusted Services Revenue of $131.1 million for the three months ended September 30, 2018, before intersegment eliminations of $(3.5) million; and
• True Health premiums revenue of $22.8 million for the three months ended September 30, 2018, before intersegment eliminations of $(0.2) million.
• Adjusted Cost of Revenue of $73.0 million and $65.7 million for the three months ended September 30, 2018 and 2017, respectively, an increase of 11.1%;
• Claims expenses of $17.0 million for the three months ended September 30, 2018;
• Adjusted Selling, General and Administrative Expenses of $55.4 million and $40.0 million for the three months ended September 30, 2018 and 2017, respectively, an increase of 38.3%;
• Adjusted EBITDA of $4.8 million and $2.6 million for the three months ended September 30, 2018 and 2017, respectively;
• Services Adjusted EBITDA of $4.1 million for three months ended September 30, 2018; and
• True Health Adjusted EBITDA of $0.7 million for the three months ended September 30, 2018.
• Adjusted Earnings (Loss) Available for Class A and Class B Shareholders of $(3.0) million and $(3.2) million for the three months ended September 30, 2018 and 2017, respectively; and
• Adjusted Earnings (Loss) per Share Available for Class A and Class B Shareholders of $(0.04) and $(0.04) for the three months ended September 30, 2018 and 2017, respectively.

Business Outlook

The fourth quarter will be the first time that we will include the results of NCH subsequent to closing the acquisition on October 1, 2018. We are not providing forward looking guidance for GAAP reported financial measures. A reconciliation of forward looking non-GAAP financial measures to the most comparable GAAP financial measure is provided in the "Guidance Reconciliation" table below. For the full year 2018, Adjusted Revenue is expected to be in the range of approximately $624.0 million to $629.0 million. The components of Adjusted Revenue include Adjusted Services Revenue, which is forecasted to be approximately $548.0 million to $552.0 million, and True Health premiums revenue, which is forecasted to be approximately $91.0 million to $92.0 million; intersegment eliminations are forecasted to be approximately $(15.5) million for the full year. Adjusted EBITDA is expected to be in the range of approximately $22.5 million to $24.5 million.

For the three months ended December 31, 2018, Adjusted Revenue is expected to be in the range of approximately $185.0 million to $190.0 million. The components of Adjusted Revenue include Adjusted Services Revenue, which is forecasted to be approximately $167.0 million to $171.0 million, and True Health premiums revenue, which is forecasted to be approximately $22.0 million to $23.0 million; intersegment eliminations are forecasted to be approximately $(4.0) million for the quarter. Within Adjusted Services Revenue, we are forecasting the contribution from NCH to be within the range of $44.0 million to $46.0 million. Adjusted EBITDA is expected to be in the range of approximately $5.0 million to $7.0 million. Adjusted EBITDA from NCH is forecasted to be approximately $4.0 million.

This "Business Outlook" section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").

Web and Conference Call Information

As previously announced, Evolent Health, Inc. will hold a conference call to discuss its third quarter performance this evening, November 6, 2018, at 5:00 p.m., Eastern Time. The conference call will be available via live webcast on the Company's Investor Relations website at http://ir.evolenthealth.com. To participate by telephone, dial 855.940.9467 or 412.317.6034 for international callers, and ask to join the Evolent Health call. Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the company's website for one week and will be available beginning later this evening. Evolent Health invites all interested parties to attend the conference call.

About Evolent Health

Evolent Health partners with leading provider organizations to achieve superior clinical and financial results in value-based care and under full-risk arrangements. With a provider heritage and over 20 years of health plan administration experience, Evolent operates in more than 30 U.S. health care markets, actively managing care across Medicare, Medicaid, commercial and self-funded adult and pediatric populations. With the experience to drive change, Evolent confidently stands by a commitment to achieve results. For more information, visit www.evolenthealth.com.

Contacts:

Financial Statement Presentation

Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units in its operating subsidiary, Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

Non-GAAP Financial Measures

In addition to disclosing financial results that are determined in accordance with GAAP, we present and discuss Adjusted Revenue, Adjusted Services Revenue, Adjusted Transformation Services Revenue, Adjusted Platform and Operations Services Revenue, Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted Depreciation and Amortization Expenses, Adjusted Total Operating Expenses, Adjusted Operating Income (Loss), Adjusted EBITDA, Services Adjusted EBITDA, True Health Adjusted EBITDA, Adjusted Earnings (Loss) Available to Class A and Class B Shareholders, Adjusted Earnings (Loss) per Share Available to Class A and Class B Shareholders and Adjusted Weighted-Average Class A and Class B Shares, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.

Adjusted Transformation Services Revenue and Adjusted Platform and Operations Services Revenue are defined as transformation services revenue and platform and operations services revenue, respectively, before the effect of intersegment eliminations and adjusted to exclude the impact of purchase accounting adjustments. In addition, the company's Adjusted Transformation Services Revenue and Adjusted Platform and Operations Services Revenue for the nine months ended September 30, 2018, include a $4.5 million adjustment related to revenue that was contracted for prior to 2018 and that was properly excluded from revenue in our 2017 results under the revenue recognition rules then in effect under Accounting Standards Codification ("ASC") 605. On January 1, 2018, we adopted the new revenue recognition rules under ASC 606 using the modified retrospective method, which required us to include this $4.5 million as part of the cumulative transition adjustment to beginning retained earnings as of January 1, 2018. Under ASC 605, and based on proportionate performance revenue recognition, we would have recognized an additional $4.5 million in revenue during 2018, primarily within our Adjusted Transformation Services Revenue. The company has therefore included this revenue, and related profit, in its adjusted results for the nine months ended September 30, 2018, as they had not been previously reported prior to 2018 and the contracts are expected to be completed within 2018. This is a one-time adjustment and it will not reoccur in future periods.

Adjusted Services Revenue is defined as the sum of Adjusted Transformation Services Revenue and Adjusted Platform and Operations Services Revenue. Adjusted Revenue is defined as the sum of Adjusted Services Revenue and True Health premiums revenue, less relevant intersegment eliminations. Management uses Adjusted Revenue, Adjusted Services Revenue, Adjusted Transformation Services Revenue and Adjusted Platform and Operations Services Revenue as supplemental performance measures because they reflect a complete view of the operational results. The measures are also useful to investors because they reflect the full view of our operational performance in line with how we generate our long term forecasts.

Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses, respectively, adjusted to exclude the impact of stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, transaction costs related to acquisitions and business combinations, securities offerings and other one-time adjustments. Management uses Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses as supplemental performance measures, which are also useful to investors, because they facilitate an understanding of our long term operational costs while removing the effect of costs that are one-time (e.g. transaction costs) and non-cash (e.g. stock-based compensation expenses) in nature. Additionally, these supplemental performance measures facilitate understanding a breakdown of our Adjusted Total Operating Expenses.

Adjusted Depreciation and Amortization Expenses is defined as depreciation and amortization expenses adjusted to exclude the impact of amortization expenses related to intangible assets acquired through acquisitions and business combinations. Management uses Adjusted Depreciation and Amortization Expenses as a supplemental performance measure because it reflects a complete view of the operational results. The measure is also useful to investors because it facilitates understanding a breakdown of our Adjusted Total Operating Expenses.

Adjusted Total Operating Expenses is defined as the sum of Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses and Adjusted Depreciation and Amortization Expenses, and reflects the adjustments made in those non-GAAP measures. Adjusted Total Operating Expenses is adjusted to exclude the impact of one-time adjustments, such as goodwill impairment, severance costs, and items arising from acquisitions and business combinations, such as changes in fair value of contingent consideration and indemnification assets.

Adjusted Operating Income (Loss) is defined as Adjusted Revenue less Adjusted Total Operating Expenses, and reflects the adjustments made in those non-GAAP measures.

Adjusted EBITDA is the sum of Services Adjusted EBITDA and True Health Adjusted EBITDA and is defined as EBITDA (net income (loss) attributable to Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses), adjusted to exclude, changes in fair value of contingent consideration and indemnification assets, income (loss) from equity method investees, other income (expense), net, net (income) loss attributable to non-controlling interests, purchase accounting adjustments, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, transaction costs related to acquisitions and business combinations and other one-time adjustments (which for the nine months ended September 30, 2018, includes the ASC 606 transition adjustment described above). Management uses Adjusted EBITDA as a supplemental performance measure because the removal of transaction costs, one-time or non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance. We believe that this measure is also useful to investors because it allows further insight into the period over period operational performance in a manner that is comparable to other organizations in our industry and in the market in general.

Adjusted Earnings (Loss) Available to Class A and Class B Shareholders is defined as earnings (loss) available to common shareholders adjusted to exclude, income (loss) from equity method investees, (provision) benefit for income taxes, changes in fair value of contingent consideration and indemnification assets, net (income) loss attributable to non-controlling interests, purchase accounting adjustments, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, transaction costs related to acquisitions and business combinations and other one-time adjustments (which for the nine months ended September 30, 2018, includes the ASC transition adjustment described above).

Adjusted Weighted-Average Class A and Class B Shares is defined as weighted average common shares (diluted) adjusted to include, in periods of net loss, the dilutive or potentially dilutive effect of the assumed conversion of Class B common shares to Class A common shares.

Adjusted Earnings (Loss) per Share Available to Class A and Class B Shareholders is defined as Adjusted Earnings (Loss) Available to Class A and Class B Shareholders divided by Adjusted Weighted-Average Class A and Class B Shares, and reflects the adjustments made in those non-GAAP measures.

Management uses Adjusted Earnings (Loss) Available to Class A and Class B Shareholders, Adjusted Weighted-Average Class A and Class B Shares and Adjusted Earnings (Loss) per Share Available to Class A and Class B Shareholders because these performance measures represent our core operating performance distributed amongst all of our investors which is not represented by the GAAP results across time due to our complex equity structure.  We believe that these measures are also useful to investors for the same reason.

These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.